C-16661 / Cyrus Therap - LARVOL DELTA

Comparative evaluation of antimicrobial peptides: effect on formation, metabolic activity and viability of Klebsiella pneumoniae biofilms. (PubMed, Front Microbiol) - "Depending on the strain, we found that planktonic growth was affected by the AMPs DJK-5, DJK-6, Onc72, and Onc112...Multi-layered biofilm aggregations were mainly negative for rhodamine B-labeled DJK-5, even 44 h after AMP treatment, indicating that certain parts of mature K. pneumoniae biofilms are not accessible for this AMP. In conclusion, we found differences in the effect of AMPs on biofilms including both increases and decreases in biofilm mass and viability."

Journal • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases

Functional study of tilapia T cell activation stimulus signal molecule CD2. (PubMed, Fish Shellfish Immunol) - "In this article, we identify the tilapia CD2 gene (GenBank accession number: OM974656; designated as OnCD2), which is predominantly expressed in various immune tissues of tilapia...The results of this study demonstrate that tilapia CD2 not only plays a role in T cell activation through its interaction with the ligand CD48, but also mediates a more complex immune regulation pathway in tilapia. This research serves as a reference for the classification of fish immune cells and enhances our understanding of T cell immunity in fish."

Journal • CD2 • CD48

Sleeping Beauty mutagenesis uncovers crucial role of Bach2 in resisting chronic tumor stimulation in CD8+ T cells (SITC 2024) - "Methods We developed a quadruple ('quad') transgenic mouse model (hCD2-Cre; Col1a1-TRE-LSL-SB100X; T2/Onc2; Rosa26-CAGGS-LSL-rtTA)...Conclusions SB-mutagenized CD8+ T cells exhibited prolonged persistence and reduced exhaustion under chronic αCD3 TCR stimulations. We highlighted the pivotal role of Bach2 in enhancing CD8+ T cell persistence amidst exhaustion cues from cancer."

IO biomarker • Melanoma • Oncology • Solid Tumor • BACH2 • CD8 • COL1A1 • HAVCR2 • PD-1

The Effect of Different Antimicrobial Peptides on Biofilm Formation of Klebsiella pneumoniae In Vitro (ASM Microbe 2024) - "A reduction of biofilm formation by more than 50% for only one of the three tested strains was demonstrated for Onc72 and Onc112. No reduction in biofilm mass was shown for Api137. Distinct AMPs such as human β-defensin 3 and LL-37 reduce biofilm formation of K. pneumoniae in vitro, while other AMPs with a described bactericidal effect against planctonic klebsiellae, such as Api137, do not suppress biofilm formation under the chosen experimental conditions."

Preclinical • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases

A selective, potent, and orally bioavailable CDK7 inhibitor demonstrates superior anti-cancer activity in colorectal cancer models (AACR 2024) - "The success of CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib underscores the promising role of targeting cell cycle regulators in anti-cancer therapy. C-16661 treatment resulted in strong inhibition of both its direct and indirect downstream targets including pS5-POLII, pT161-CDK1, c-MYC, and MCL1 in HCT116, a human colorectal carcinoma cell line. While C-16661 exhibited good PK profiles in animals, it demonstrated excellent tumor growth inhibition without any tolerability issues in a colorectal cancer CDX mouse efficacy model."

Late-breaking abstract • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CDK1 • MYC

Cyrus announces research results on anticancer drugs targeting GSPT1, SOS1, and CDK7 at the U.S. AACR [Google translation] (HIT News) - "Cyrus...announced on the 8th...that it had made three presentations at the American Association for Cancer Research...Through this announcement, the company revealed the results showing that CYRS1542 was effective in treating neuroendocrine tumors (small cell lung cancer, neuroendocrine prostate cancer, etc.) that have a very poor clinical prognosis and lack appropriate treatment options. They also disclosed various cell and animal test results showing that it has a wider therapeutic index compared to competing clinical-stage substances...the drug efficacy evaluation results of various rodent models transplanted with KRAS or EGFR mutant non-small cell carcinoma (NSCLC) or pancreatic cancer (PDAC) cells showed that CK-1001 combination therapy kills cancer cells better than existing treatments....C-16661 had high selectivity for CDK7 and properties suitable for oral administration, and strongly inhibited the growth of various cancer cells."

Preclinical • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor